Fresh findings explore caregiver burden, bipolar risk in PCOS, mood tracking tools, and the link between metabolism and ...

Are substance-induced psychosis and primary psychosis fundamentally different? And if they are, does it matter?

Compared with placebo, xanomeline/trospium as an add-on to atypical antipsychotics has not reached the threshold for a ...

A team of scientists in California has tweaked the hallucinogenic drug LSD to make it usable to treat schizophrenia and other neuropsychiatric and neurodegenerative diseases.According to the ...

A new study led by scientists from the University of Zurich and the University Hospital of Psychiatry Zurich has found a ...

Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments ...

Autism's history is filled with misconceptions. Understanding the science helps us move past outdated myths, support autistic ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...

BMS has reported topline outcomes from the ARISE trial of Cobenfy as an adjunctive treatment to atypical antipsychotics for schizophrenia.

Individuals who sought hospital care or emergency treatment due to cannabis use showed a higher likelihood of developing ...

With a lack of real breakthroughs since the 1960s, older methods such as electrical-based therapies are experiencing a revival in psychiatry.

A new study led by the University of Zurich has shown that evidence of genetic susceptibility to schizophrenia can be found in the retina. This finding could help improve the early detection of the ...